Modulation of basal ganglia neurotransmission by the classical antipsychotic fluphenazine is due in part to the blockade of dopamine D1-receptors

Molecular Brain Research

Volumn 49, Issue 1-2, 1997, Pages 197-210

  Coirini, Héctor ^a   Källström, Lillemor ^b   Wiesel, Frits Axel ^b   Johnson, Allan E ^b  

^a INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antipsychotics; Basal ganglion; D1 receptor; D2 receptor; Entopeduncular nucleus; Glutamic acid decarboxylase (GAD); Proenkephalin; Striatum

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; FLUPHENAZINE DECANOATE; GLUTAMATE DECARBOXYLASE; MESSENGER RNA; PREPROENKEPHALIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CONTROLLED STUDY; ENTOPEDUNCULAR NUCLEUS; FEMALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR BINDING;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; DOPAMINE ANTAGONISTS; ENKEPHALINS; FEMALE; FLUPHENAZINE; GLUTAMATE DECARBOXYLASE; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; SYNAPTIC TRANSMISSION; TRANSCRIPTION, GENETIC;

ANIMALIA;

EID: 0343035563     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(97)00144-7     Document Type: Article

References (132)

1. Abood M.E., Eberwine J.H., Erdelyi E., Evans C.J. Regulation of both preproenkaphalin mRNA and its derived opioids by haloperidol - a method for measurement of peptides and mRNA in the same tissue extract. Mol. Brain Res. 8:1990;243-248.
2. 3H]SCH-23390. J. Chem. Neuroanat. 5:1992;357-366.
3. 1 receptor containing neurons. Brain Res. 410:1987;1-11.
4. 3H]spiroperidol. J. Pharmacol. Exp. Ther. 233:1985;527-538.
5. 1 receptors in brain demonstrated with digital subtraction autoradiography. J. Neurosci. 7:1987;213-222.
6. Angulo J., Cadet J., McEwen B. Effect of typical and atypical neuroleptic treatment on protachykinin mRNA levels in the striatum of the rat. Neurosci. Lett. 113:1990;217-221.
7. 2-receptors in the regulation of proenkephalin mRNA abundance in the striatum and accumbens of the rat brain. J. Neurochem. 54:1992;1889-1894.
8. Angulo J.A., Cadet J.L., Wooley C.S., Suber F., McEwen B.S. Effect of chronic typical and atypical neuroleptic treatment on proenkephalin mRNA levels in the striatum and nucleus accumbens of the rat. J. Neurochem. 54:1990;1889-1894.
9. Angulo J.A., Christoph G., Manning R., Burkhart B., Davis L. Reduction of dopamine receptor activity differentially alters striatal neuropeptide mRNA levels. Adv. Exp. Med. Biol. 221:1987;385-391.
10. 2 mRNA and receptor levels in the striatum and nucleus accumbens of the rat. Mol. Brain Res. 11:1991;161-166.
11. Angulo J.A., Davis L., Burkhart B., Christoph G.R. Reduction of striatal dopaminergic neurotransmission elevates striatal proenkephalin mRNA. Eur. J. Pharmacol. 130:1986;343-344.
12. Angulo J.A., McEwen B.S. Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens. Brain Res. Rev. 19:1994;1-28.
13. 5-enkaphalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: implications for the pathogenesis of neuroleptic-induced movement disorders. Exp. Neurol. 117:1992;17-27.
14. 3H]SCH 23390 binding to dopamine D1-receptors in the basal ganglia of the cat and primate: delineation of the striosomal compartments and pallidal and nigral sudivisions. Neuroscience. 26:1988;101-119.
15. Boldry R.C., Papa S.M., Kask A.M., Chase T.N. MK-801 revereses effects of chronic levodopa on D1 and D2 dopmaine agonist-induced rotational behavior. Brain Res. 692:1995;259-264.
16. 125I]iodosulpiride. Neuroscience. 20:1987;117-155.
17. 2 subtypes of dopamine receptors in rat brain. J. Neurosci. 6:1986;3177-3188.
18. Bu D.-F., Erlander M.G., Hitz B.C., Tillakartne K., Kaufman D.L., Wagner-McPherson C.B., Evans G.A., Tobin A.J. Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. Proc. Natl. Acad. Sci. USA. 89:1992;2115-2119.
19. Burt D.R., Creese I., Snyder S.H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science. 196:1976;326-328.
20. Caboche J., Vernier P., Julien J.-F., Rogard M., Mallet J., Besson M.-J. Parallel decrease of glutamic acid decarboxylase and proenkephalin mRNA in the rat striatum following chronic treatment with a dopaminergic D1 antagonist and D2 agonist. J. Neurochem. 56:1991;428-435.
21. Caboche J., Vernier P., Rogard M., Besson M.-J. Haloperidol increases PPE mRNA levels in the caudal part of the nucleus accumbens in the rat. NeuroReport. 4:1993;551-554.
22. 2 receptor mRNA levels in the striatum: effects of unilateral intrastriatal injections of 6-hydroxydopamine. Mol. Brain Res. 12:1992;59-67.
23. 3H]N-n-propylnorapomorphine. Brain Res. 375:1986;135-149.
24. Castel M.-N., Morino P., Nylander I., Terenius L., Hökfelt T. Differential dopaminergic regulation of the neurotensin striatonigral and striatopallidal pathways in the rat. Eur. J. Pharmacol. 262:1994;1-10.
25. Castel M.N., Morino P., Hökfelt T. Modulation of the neurotensin striato-nigral pathway by D1 receptors. NeuroReport. 5:1993;281-284.
26. Cepeda C., Buchwald N.A., Levine M.S. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc. Natl. Acad. Sci. USA. 90:1993;9576-9580.
27. Charuchinda C., Supavilai P., Karobath M., Palacios J.M. Dopamine D2-receptors in the rat brain: autoradiographic visualization using a high-affinity selective agonist ligand. J. Neurosci. 7:1987;1352-1360.
28. Chen J.F., Aloyo V.J., Weiss B. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 receptors, D2 receptor mRNA and proenkephalin mRNA, and increases mu opioid receptors in mouse striatum. Neuroscience. 54:1993;669-680.
29. Chesselet M.-F., Mercugliano M., Soghomonian J.-J., Salin P., Qin Y., Gonzales C. Regulation of glutamic acid decarboxylase gene expression in efferent neurons of the basal ganglia. Prog. Brain Res. 99:1993;143-154.
30. M.-F. Chesselet, J.-J. Soghomonian, P. Salin, Anatomical localization and regulation of somatostatin gene expression in the basal ganglia and its clinical implications, in: Somatostatin and its Receptors, Wiley, Chichester, UK, 1995, pp. 51-64.
31. Chesselet M.-F., Weiss L., Wuenschell C., Tobin A.J., Affolter H.-U. Comparative distribution of mRNAs for glutamic acid decarboxylase, tyrosine hydroxylase, and tachykinins in the basal ganglia: in situ hybridization study in rodent brain. J. Comp. Neurol. 262:1987;125-140.
32. Christensen A.V., Arnt J., Hyttel J., Larsen J.-J., Svendson O. Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci. 34:1984;1529-1540.
33. 3H]CV 205-502. Brain Res. 440:1988;123-132.
34. 3H-haloperidol. Life Sci. 17:1975;993-1002.
35. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;717-719.
36. Creese I., Chen A. Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390. Eur. J. Pharmacol. 109:1985;127-128.
37. 1 dopamine receptor in the rat brain: quantitative autoradiographic localization using an iodinated ligand. Neuroscience. 26:1988;83-100.
38. De Ceballos M.L., Jenner P., Marsden C.D. Acute and repeated administration of sulpiride alters Met- and Leu-enkephalin content of rat brain. Neurosci. Lett. 68:1986;322-326.
39. Delfs J.M., Anegawa N.J., Chesselet M.-F. Glutamate decarboxylase mRNA in rat pallidum: comparison of the effects of haloperidol, clozapine and combined haloperidol-scopolamine treatments. Neuroscience. 66:1995;67-80.
40. Delfs J.M., Ciaramitaro V.M., Soghomonian J.-J., Chesselet M.-F. Unilateral nigrostriatal lesions induce a bilateral increase in glutamate decarboxylase messenger RNA in the reticular thalamic nucleus. Neuroscience. 71:1996;383-395.
41. Delfs J.M., Ellison G.D., Mercugliano M., Chesselet M.-F. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Exp. Neurol. 133:1995;175-188.
42. Delfs J.M., Yu L., Ellison G.D., Reisine T., Chesselet M.-F. Regulation of μ-opioid receptor mRNA in rat globus pallidus: effects of enkephalin increases induced by short and long-term haloperidol administration. J. Neurochem. 63:1994;777-780.
43. Dewey K.J., Fibiger H.C. The effect of dose and duration of chronic pimozide administration on dopamine receptor supersensitivity. Naunyn-Schmeiderberg's Arch. Pharmacol. 322:1983;261-270.
44. 1 dopamine receptors during development. J. Neurochem. 61:1993;1255-1262.
45. Duncan G.E., Criswell H.E., McCown T.J., Paul I.A., Mueller R.A., Breese G.R. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 243:1987;1027-1034.
46. Egan M.F., Hurd Y., Hyde T.M., Weinberger D.R., Wyatt R.J., Kleinman J.E. Alterations in mRNA levels and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse. 18:1994;178-189.
47. Erlander M.G., Tillakaratne N.J., Feldblum S., Patel N., Tobin A.J. Two genes encode distinct glutamate decarboxylases. Neuron. 7:1991;91-100.
48. Erlander M.G., Tobin A.J. The structural and functional heterogeneity of glutamic acid decarboxylase: a review. Neurochem. Res. 16:1991;215-226.
49. Esclapez M., Tillakaratne N.J.K., Tobin A.J., Houser C.R. Comparative localization of mRNAs encoding two forms of glutamic acid decarboxylase with nonradioactive in situ hybridization methods. J. Comp. Neurol. 331:1993;339-362.
50. Farde L., Nordström A.-L., Wiesel F.-A., Pauli S., Haldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 49:1992;538-544.
51. Fleminger S., Rupniak N.M.J., Hall M.D., Jenner P., Marsden C.D. Changes in apomorphine-induced stereotopy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors but not with increases in D-1 receptors. Biochem. Pharmacol. 32:1983;2921-2927.
52. J. Gagnon, J.M. Roth, R. Hofman, K.A. Haycock, D.S. Feldman Jr., SuperANOVA, Abacus Concepts, Berkeley, CA, 1989.
53. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu. Rev. Neurosci. 15:1992;285-320.
54. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
55. Gerfen C.R., McGinty J.F., Young W.S. III Dopamine differentially regulates dynorphin, Substance P, and enkephalin in striatal neurons: in situ hybridization histochemical analysis. J. Neurosci. 11:1991;1016-1031.
56. 3H]γ-aminobutyric acid in the rat neostriatum. II. Opposing effects of D1 and D2 dopamine receptor stimulation in the dorsal caudate putamen Neuroscience. 19:1986;1109-1117.
57. Gitlin M.J., Midha K.K., Fogelson D., Nuechterlein K. Persistence of fluphenazine in plasma after decanoate withdrawal. J. Clin. Psychopharmacol. 8:1988;53-56.
58. Goss J.R., Kelley A.B., Johnson S.A., Morgan D.G. Haloperidol treatment increases D2-receptor protein independently of RNA levels in mice. Life Sci. 48:1991;1015-1022.
59. 2 receptors. Psychopharmacology. 103:1991;6-18.
60. 2 receptor in the rat brain. Pharmacol. Toxicol. 60:1987;359-363.
61. 1-receptors to striatonigral neurons. Brain Res. 528:1990;317-322.
62. Hess E.J., Norman A.B., Creese I. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors. J. Neurosci. 8:1988;2361-2370.
63. Hietala J., Seppala T., Lappalainen J., Syvalahti E. Quantification of SCH-39166, a novel selective D1 dopamine receptor antagonist, in rat brain and blood. Psychopharmacology. 106:1992;455-458.
64. Hong J.S., Yang H.-Y.T., Costa E. Substance P content of substantia nigra after chronic treatment with antischizophrenic drugs. Neuropharmacology. 17:1978;83-85.
65. Jenner P., Kerwin R., Rupniak N.M.J., Murugaiah K., Hall M.D., Fleminger S., Marsden C.D. Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats. J. Neural Transm. 18:1983;205-212.
66. Jiang H.-K., McGinty J.F., Hong J.S. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes. Brain Res. 507:1990;57-64.
67. 1-receptor binding in the entopeduncular nucleus. NeuroReport. 6:1995;933-936.
68. Johnson A.E., Corini H., Källström L., Wiesel F.-A. Characterization of dopamine receptor binding sites in the subthalamic nucleus. NeuroReport. 5:1994;1836-1838.
69. Johnson A.E., Liminga U., Lidén A., Lindefors N., Gunne L., Wiesel F.-A. Chronic treatment with a classical neuroleptic alters excitatory amino acid transmission and GABA-ergic transmission in specific regions of the rat brain. Neuroscience. 63:1994;1003-1020.
70. Kamer R.S., Turi A.R., Solomon P.R., Kaplan L.J. Increased mesolimbic dopamine binding following chronic haloperidol treatment. Psychopharmacology. 72:1981;261-263.
71. Kaufman D.L., Houser C.R., Tobin A.J. Two forms of the γ-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. J. Neurochem. 56:1991;720-723.
72. 125I]Epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors Life Sci. 49:1991;617-628.
73. 125I]epidepride. Brain Res. 1993:1993;237-243.
74. Kobayashi Y., Kaufman D.L., Tobin A.J. Glutamic acid decarboxylase cDNA: nucleotide sequence encoding an enzymatically active fusion protein. J. Neurosci. 7:1987;2768-2772.
75. 3H]eticlopride in the rat brain: evidence for selective labelling of dopamine receptors. Eur. J. Pharmacol. 120:1986;217-226.
76. 3H-raclopride. Biochem. Pharmacol. 34:1985;2251-2259.
77. Livezey R.T., Pearce L.B., Kornetsky C. The effect of MK-801 and SCH23390 on the expression and sensitization of morphine-induced oral stereotypy. Brain Res. 692:1995;93-98.
78. MacKenzie R.G., Zigmond M.J. Chronic neuroleptic treatment increases D-2 but not D-1 receptors in rat striatum. Eur. J. Pharmacol. 113:1985;159-165.
79. 3H]SCH 23390 as ligands for the D-1 dopamine receptor. J. Neurochem. 51:1988;391-397.
80. 1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques. Neuroscience. 46:1992;959-971.
81. Marder S.R., Hubbard J.W., Van Putten T., Midha K.K. Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacology. 98:1989;433-439.
82. Martin D.L., Rimvall K. Regulation of γ-aminobutyric acid synthesis in the brain. J. Neurochem. 60:1993;395-407.
83. Meador-Woodruff J.H., Mansour A., Healy D.J., Kuehn R., Zhou Q.-Y., Bunzow J.R., Akil H., Civelli O., Watson S.J.J. Comparison of the distribution of D1 and D2 receptor mRNAs in rat brain. Neuropsychopharmacology. 5:1991;231-242.
84. Merchant K., Letter A., Gibb J., Hanson G. Changes in the limbic neurotensin systems induced by dopaminergic drugs. Eur. J. Pharmacol. 153:1988;1-9.
85. Merchant K.M., Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc. Natl. Acad. Sci. USA. 90:1993;3447-3451.
86. Merchant K.M., Gibb J.W., Hanson G.R. Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and nucleus accumbens. Eur. J. Pharmacol. 160:1989;409-412.
87. Mercugliano M., Chesselet M.F. Clozapine decreases enkephalin mRNA in rat striatum. Neurosci. Lett. 136:1992;10-14.
88. Mercugliano M., Saller C.F., Salama A.I., U'Prichard D.C., Chesselet M.-F. Clozapine and haloperidol have differential effects on glutamic acid decarboxylase mRNA in the pallidal nuclei of the rat. Neuropsychopharmacology. 6:1992;179-187.
89. r 67,000) in the basal ganglia of the rat. J. Comp. Neurol. 318:1992;245-254.
90. Midha K.K., Hubbard J.W., Marder S.R., Hawes E.M., Van Putten T., McKay G., May P.R.A. The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate. Psychopharmacology. 93:1987;369-373.
91. Mocchetti I., Naranjo J., Costa E. Regulation of striatal enkephalin turnover in rats receiving antagonists of specific dopamine recptor subtypes. J. Pharmacol. Exp. Ther. 241:1987;1120-1124.
92. Mocchetti I., Schwartz J., Costa E. Use of mRNA hybridization and radioimmunoassay to study mechanisms of drug-induced accumulation of enkephalins in rat brain structures. Mol. Pharmacol. 28:1985;86-91.
93. 2 responses in 6-hydroxydopamine model of Parkinson's disease. Eur. J. Pharmacol. 182:1990;611-612.
94. 2 antagonists. Neuroscience. 25:1988;525-532.
95. Muller P., Seeman P. Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, α-noradrenergic and naloxone receptors. Life Sci. 21:1977;1751-1758.
96. Muller P., Seeman P. Dopaminergic supersensitivity after neuroleptics: time-course and specificity. Psychopharmacology. 60:1978;1-11.
97. Murugaiah K., Theodorou A., Mann S., Clow A., Jenner P., Marsden C.D. Chronic continuous administration of neuroletic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum. Nature. 296:1982;570-572.
98. 3H]piquindone binding sites (dopamine D2 receptors) in rat brain. Eur. J. Pharmacol. 121:1986;387-393.
99. 2-receptor occupancy during low-dose treatment with haloperidol decanoate. Am. J. Psychiatry. 152:1995;173-178.
100. Nylander I., Terenius L. Chronic haloperidol and clozapine differentially affect dynorphin peptides and substance P in basal ganglia of the rat. Brain Res. 380:1986;34-41.
101. O'Dell S.J., La Hoste G.J., Widmark C.B., Shapiro R.M., Potkin S.G., Marshall J.F. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse. 6:1990;146-153.
102. Papa S.M., Engber T.M., Boldry R.C., Chase T.N. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonist. Eur. J. Pharmacol. 232:1993;247-253.
103. Parent A., Hazrati L.-N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop Brain Res. Rev. 20:1995;91-127.
104. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, New York, NY, 1986.
105. Rasband W.S., Bright D.S. NIH image: a public domain image processing program for the Macintosh. Microbeam Anal. Soc. J. 4:1995;137-149.
106. Romano G.J., Shivers B.D., Harlan R.E., Howells R.D., Pfaff D.W. Haloperidol increases proenkephalin mRNA levels in the caudate-putamen of the rat: a quantitative study at the cellular level using in situ hybridization. Mol. Brain Res. 2:1987;33-41.
107. Rosen H., Douglass J., Herbert E. Isolation and characterization of of the rat proenkepahalin gene. J. Biol. Chem. 259:1984;14309-14313.
108. Rupniak N.M.J., Jenner P., Marsden C.D. The effect of chronic neuroleptic administration on cerebral dopamine receptor function. Life Sci. 32:1983;2289-2311.
109. Rupniak N.M.J., Kilpatrick G., Hall M.D., Jenner P., Marsden C.D. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Psychopharmacology. 84:1984;512-519.
110. 3H]SCH 23390. Brain Res. 375:1986;291-301.
111. See R.W., Toga A.W., Ellison G. Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J. Neural Transm. - Gen. Sect. 82:1990;93-109.
112. P. Seeman, Dopamine receptors: clinical correlates, in: F.E. Bloom, D.J. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress, Raven, New York, NY, 1995, pp. 295-302.
113. Seeman P., Grigoriadis D. Dopamine receptors in brain and periphery. Neurochem. Int. 10:1987;1-25.
114. Soghomonian J.-J., Chesselet M.F. Effects of nigrostriatal lesions on the levels of messenger RNAs encoding two isoforms of glutamate decarboxylase in the globus pallidus and entopeduncular nucleus of the rat. Synapse. 11:1992;124-133.
115. Soghomonian J.-J., Gonzales C., Chesselet M.-F. Messenger RNAs encoding glutamate-decarboxylases are differentially affected by nigrostriatal lesions in subpopulations of striatal neurons. Brain Res. 576:1992;68-79.
116. 2 receptors. J. Pharmacol. Exp. Ther. 266:1993;1374-1384.
117. Surmeier D.J., Reiner A., Levine M.S., Ariano M.A. Are neostriatal dopamine receptors co-localized? Trends Neurosci. 16:1993;299-305.
118. Surmeier D.J., Song W.-J., Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16:1996;6579-6591.
119. Tang F., Costa E., Schwartz J.P. Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injection of haloperidol for 2 to 3 weeks. Proc. Natl. Acad. Sci. USA. 80:1983;3841-3844.
120. Testa R., Abbiati G., Cesarani R., Restelli G., Vanasia A., Barone D., Gobbi M., Mennini T. Profile of in vitro binding affinities of neuroleptics at different rat brain receptors: cluster analysis comparison with pharmacological and clinical profiles. Pharm. Res. 6:1989;571-577.
121. Thal L.J., Sharpless N.S., Hirschhorn I.D., Horowitz S.G., Makman M.H. Striatal Met-enkephalin concentration increases following nigrostriatal denervation. Biochem. Pharmacol. 32:1983;3297-3301.
122. 2 dopamine receptor mRNA level. Neurosci. Lett. 111:1990;303-308.
123. Verma A., Kulkarni S.K. D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats. Psychopharmacology. 109:1992;477-483.
124. Voorn P., Roest G., Groenewegen H.J. Increase of proenkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res. 412:1987;391-396.
125. Wadenberg M.-L. Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J. Neural Transm. - Gen. Sect. 89:1992;49-59.
126. Wanibuchi F., Usuda S. Synergistic effects between D-1 and D-2 antagonists on catalepsy in rats. Psychopharmacology. 102:1990;339-342.
127. 1 receptors. Brain Res. 622:1993;325-329.
128. Wilmot C.A., Szczepanik A.M. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res. 487:1989;288-298.
129. Xu S., Monsma F. Jr., Sibley D.R., Creese I. Regulation of D1A and D2 dopamine receptor mRNA during ontogenesis, lesion and chronic antagonist treatment. Life Sci. 50:1992;383-396.
130. W.S. Young III, In situ hybridization with oligodeoxyribonucleotide probes, in: D.G. Wilkinson (Ed.), In Situ Hybridization: a Practical Approach, IRL, Oxford, UK, 1992, pp. 33-44.
131. Young III W.S., Bonner T.I., Brann M.R. Mesencephalic dopmaine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA. 83:1986;9827-9831.
132. Yuan P.-Q., Grånäs C., Källström L., Yu J., Huhman K., Larhammar D., Albers H.E., Johnson A.E. Differential distribution of GAD65 and GAD67 mRNA in the entopeduncular nucleus of the rat. Neuroscience. 78:1997;87-97.